【摘要】 目的 探讨罗格列酮对T2DM患者血浆内脏脂肪特异性丝氨酸蛋白酶抑制剂(vaspin)水平的影响。 方法 将105例研究对象分为NGT、IGR)和T2DM组。T2DM组用罗格列酮治疗12周。检测人体测量参数和所需生化指标，采用稳态模式评估胰岛素抵抗指数(HOMA-IR)及β细胞功能指数(HOMA-IS)，用酶联免疫吸附法(ELISA)测定血浆Vaspin浓度。分析Vaspin浓度及各参数间的关系及罗格列酮治疗前后vaspin浓度的变化。结果 T2DM组空腹血浆Vaspin水平(1.19±0.74)µg/L高于NGT 0.54±0.28)µg/L、IGR组(0.46±0.26)µg/L(P<0.05), 而NGT组和IGR组间差异无统计学意义。血浆vaspin水平与FINS和HOMA-IR呈明显正相关。罗格列酮治疗12周后，T2DM组空腹血浆vaspin水平明显下降[(1.19±0.74)µg/L vs(0.91±0.54 )µg/L,P<0.05)]。结论 T2DM组血浆vaspin水平增高，而罗格列酮治疗在控制血糖及改善胰岛素敏感性同时，降低了血浆vaspin水平。

　　【关键词】vaspin;糖尿病，2型;胰岛素敏感性;罗格列酮

　　Elevated circulating vaspin levels decreased by rosiglitazone therapy in T2DM patients with poor glycemic control on metformin alone  HE Jia, YANG Gang-yi, LI Ling, et al. Department of Clinical Biochemistry, Chongqing Medical University, Chongqing 400016, China

　　Corresponding author: LI Ling, E-mail: lingli31@yahoo.com.cn

　　【Abstract】Objective To investigate the effect of rosiglitazone therapy on plasma vaspin in T2DM patients inadequately controlled on metformin alone. Methods A total of 105 subjects, including 37 subjects with normal glucose tolerance (NGT), 37 subjects with impaired glucose regulating (IGR), and 31 T2DM patients with poor glycemic control on metformin alone, were enrolled in this study. The T2DM patients were treated with rosiglitazone for 12 weeks. The somatometric parameters and the needed biochemical indices were determined. The homeostasis model assessment (HOMA) was adopted to evaluate the insulin resistance (IR) and islet β cell function index (IS). ELISA was used to determine the plasma vaspin concentration. An analysis on the correlation between vaspin concentration and all parameters was carried out and the changes in vaspin concentration after the rosiglitazone treatment were observed. Results Fasting plasma vaspin level was higher in the T2DM patients with poor glycemic control than that in the IGR and NGT groups (1.19±0.74 vs 0.46±0.26 vs 0.54±0.28 ug/L, P<0.05). There was no difference between IGR and NGT groups. In the T2DM patients, fasting plasma vaspin concentration was significantly decreased after rosiglizatone therapy for 12 weeks (1.19 ± 0.74 vs 0.91 ± 0.54 lg/L, P<0.05), accompanied with significant amelioration of insulin sensitivity and glucose control. Plasma vaspin levels were positively associated with the fasting insulin (FIns) and the homeostasis model assessment of IR (HOMA-IR). Conclusion Plasma vaspin level is higher in T2DM patients with poor glycemic control. And rosiglitazone therapy decreases plasma vaspin level through glucose and insulin sensitivity regulation.

　　【Key words】Vaspin; Diabetes mellitus, type 2; Insulin sensitivity; Rosiglitazone